Current HIV Research

Author(s): Seyed Jalal Kiani, Tahereh Donyavi* and Farah Bokharaei-Salim

DOI: 10.2174/011570162X326491240906064322

DownloadDownload PDF Flyer Cite As
Detection Of CCR5 Delta-32 Mutation Using High-Resolution Melting Curve Analysis: Challenges and Facts

Page: [368 - 373] Pages: 6

  • * (Excluding Mailing and Handling)

Abstract

Introduction: The C-C chemokine receptor type 5 (CCR5) is a major co-receptor for human immunodeficiency virus (HIV). Some individuals carry the CCR5 delta-32 genetic polymorphism. People with homozygous CCR5 delta-32 gene are nearly completely resistant to HIV-1 infection. High-resolution melting curve (HRM) analysis is a post-PCR technique utilized for identifying genetic variations in a quick, affordable, and closed-tube assay. The objective of this study was to develop an HRM assay for easy detection of delta-32 mutations.

Materials and Methods: DNA was extracted from peripheral blood mononuclear cells. HRM was performed to detect delta-32 mutation. The study investigated the impact of various factors, including annealing temperature, template concentration, touchdown PCR, additives, amplicon size, and program settings, on HRM Tm differentiation.

Results: It was expected that there would be a 4°C Tm difference between amplicons with and without delta-32 mutation, but the test showed a difference of only 2.3°C. In attempts to identify heterozygote delta-32 variants, a Tm difference of only 0.4°C could be achieved. Various modifications were applied, such as adjusting the template concentration, using touchdown PCR, and adding DMSO and glycerol. However, none of these changes helped to differentiate the Tm effectively, especially in delta-32 heterozygote samples.

Conclusion: The HRM test identified four samples with heterozygote mutations in each HIV-infected (8.89%) and control (5.72%) groups. More importantly, this study showed that identifying the delta-32 mutation of the CCR5 gene using HRM assay is not as straightforward as previously suggested in some literature, and it requires special setup conditions.

Keywords: High-resolution melting curve analysis (HRM), human immunodeficiency virus (HIV), chemokine receptor R5 (CCR5), delta-32 deletion, mutation, genetic diversity.

Graphical Abstract

[1]
Berger EA, Murphy PM, Farber JM. Chemokine receptors as HIV-1 coreceptors: Roles in viral entry, tropism, and disease. Annu Rev Immunol 1999; 17(1): 657-700.
[http://dx.doi.org/10.1146/annurev.immunol.17.1.657] [PMID: 10358771]
[2]
Alkhatib G, Berger EA. HIV coreceptors: From discovery and designation to new paradigms and promise. Eur J Med Res 2007; 12(9): 375-84.
[PMID: 17933717]
[3]
Brelot A, Chakrabarti LA. CCR5 revisited: How mechanisms of HIV entry govern AIDS pathogenesis. J Mol Biol 2018; 430(17): 2557-89.
[http://dx.doi.org/10.1016/j.jmb.2018.06.027] [PMID: 29932942]
[4]
Blanpain C, Libert F, Vassart G, Parmentier M. CCR5 and HIV Infection. Receptors Channels 2002; 8(1): 19-31.
[http://dx.doi.org/10.3109/10606820212135] [PMID: 12402506]
[5]
Michael NL, Louie LG, Rohrbaugh AL, et al. The role of CCR5 and CCR2 polymorphisms in HIV-1 transmission and disease progression. Nat Med 1997; 3(10): 1160-2.
[http://dx.doi.org/10.1038/nm1097-1160] [PMID: 9334732]
[6]
Eugen-Olsen J, Iversen AKN, Garred P, et al. Heterozygosity for a deletion in the CKR-5 gene leads to prolonged AIDS-free survival and slower CD4 T-cell decline in a cohort of HIV-seropositive individuals. AIDS 1997; 11(3): 305-10.
[http://dx.doi.org/10.1097/00002030-199703110-00007] [PMID: 9147421]
[7]
Laurichesse JJ, Persoz A, Theodorou I, Rouzioux C, Delfraissy JF, Meyer L. Improved virological response to highly active antiretroviral therapy in HIV-1-infected patients carrying the CCR5 Δ32 deletion. HIV Med 2007; 8(4): 213-9.
[http://dx.doi.org/10.1111/j.1468-1293.2007.00455.x] [PMID: 17461848]
[8]
Marmor M, Sheppard HW, Donnell D, et al. Homozygous and heterozygous CCR5-Δ32 genotypes are associated with resistance to HIV infection. J Acquir Immune Defic Syndr 2001; 27(5): 472-81.
[http://dx.doi.org/10.1097/00126334-200108150-00009] [PMID: 11511825]
[9]
Liu S, Kong C, Wu J, Ying H, Zhu H. Effect of CCR5-Δ32 heterozygosity on HIV-1 susceptibility: A meta-analysis. PLoS One 2012; 7(4): e35020.
[http://dx.doi.org/10.1371/journal.pone.0035020] [PMID: 22496885]
[10]
Ni J, Wang D, Wang S. The CCR5-Delta32 genetic polymorphism and HIV-1 infection susceptibility: A meta-analysis. Open Med (Wars) 2018; 13(1): 467-74.
[http://dx.doi.org/10.1515/med-2018-0062] [PMID: 30426084]
[11]
de Roda Husman AM, Koot M, Cornelissen M, et al. Association between CCR5 genotype and the clinical course of HIV-1 infection. Ann Intern Med 1997; 127(10): 882-90.
[http://dx.doi.org/10.7326/0003-4819-127-10-199711150-00004] [PMID: 9382366]
[12]
França LTC, Carrilho E, Kist TBL. A review of DNA sequencing techniques. Q Rev Biophys 2002; 35(2): 169-200.
[http://dx.doi.org/10.1017/S0033583502003797] [PMID: 12197303]
[13]
Slatko BE, Gardner AF, Ausubel FM. Overview of next-generation sequencing technologies. Curr Protoc Mol Biol 2018; 122(1): e59.
[http://dx.doi.org/10.1002/cpmb.59] [PMID: 29851291]
[14]
Wittwer CT. High-resolution DNA melting analysis: advancements and limitations. Hum Mutat 2009; 30(6): 857-9.
[http://dx.doi.org/10.1002/humu.20951] [PMID: 19479960]
[15]
Reed GH, Kent JO, Wittwer CT. High-resolution DNA melting analysis for simple and efficient molecular diagnostics. Pharmacogenomics 2007; 8(6): 597-608.
[http://dx.doi.org/10.2217/14622416.8.6.597]
[16]
Montgomery JL, Sanford LN, Wittwer CT. High-resolution DNA melting analysis in clinical research and diagnostics. Expert Rev Mol Diagn 2010; 10(2): 219-40.
[http://dx.doi.org/10.1586/erm.09.84] [PMID: 20214540]
[17]
Kiani SJ, Ramshini M, Bokharaei-Salim F, et al. High resolution melting curve analysis for rapid detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants. Acta Virol 2023; 67(1): 91-8.
[http://dx.doi.org/10.4149/av_2023_109] [PMID: 36950889]
[18]
Ramshini M, Bokharaei-Salim F, Donyavi T, Khoshmirsafa M, Ghorbani S, Khatami A, et al. Single nucleotide polymorphism in toll-like receptor 3 gene as a potential risk factor for severe outcome of coronavirus disease 2019. Rev Res Med Microbiol 2019.
[19]
Lopalco L. CCR5: From natural resistance to a new anti-HIV strategy. Viruses 2010; 2(2): 574-600.
[http://dx.doi.org/10.3390/v2020574] [PMID: 21994649]
[20]
Vossen RHAM, Aten E, Roos A, den Dunnen JT. High-resolution melting analysis (HRMA)-more than just sequence variant screening. Hum Mutat 2009; 30(6): 860-6.
[http://dx.doi.org/10.1002/humu.21019] [PMID: 19418555]
[21]
Donyavi T, Bokharaei-Salim F, Nahand JS, et al. Evaluation of CCR5-Δ32 mutation among individuals with high risk behaviors, neonates born to HIV-1 infected mothers, HIV-1 infected individuals, and healthy people in an Iranian population. J Med Virol 2020; 92(8): 1158-64.
[http://dx.doi.org/10.1002/jmv.25658] [PMID: 31854469]
[22]
Nansen A, Christensen JP, Andreasen SØ, Bartholdy C, Christensen JE, Thomsen AR. The role of CC chemokine receptor 5 in antiviral immunity. Blood 2002; 99(4): 1237-45.
[http://dx.doi.org/10.1182/blood.V99.4.1237] [PMID: 11830471]
[23]
Rasmussen H, Werge T. A closed-tube assay for genotyping of the 32-bp deletion polymorphism in the chemokine receptor 5 (CCR5) gene: Dissociation analysis of amplified fragments of DNA. Mol Cell Probes 2007; 21(1): 8-11.
[http://dx.doi.org/10.1016/j.mcp.2006.05.003] [PMID: 16879946]
[24]
Nischalke HD, Nattermann J, Lichterfeld M, et al. Rapid determination of the Δ32 deletion in the human CC-chemokine receptor 5 (CCR5) gene without DNA extraction by lightcycler real-time polymerase chain reaction. AIDS Res Hum Retroviruses 2004; 20(7): 750-4.
[http://dx.doi.org/10.1089/0889222041524634] [PMID: 15307921]
[25]
Korbie DJ, Mattick JS. Touchdown PCR for increased specificity and sensitivity in PCR amplification. Nat Protoc 2008; 3(9): 1452-6.
[http://dx.doi.org/10.1038/nprot.2008.133] [PMID: 18772872]
[26]
Roux KH. Single-step PCR optimization using touchdown and stepdown PCR programming. Methods Mol Biol 2002; 192: 31-6.
[http://dx.doi.org/10.1385/1-59259-177-9:031]
[27]
Rahimi H, Farajollahi MM, Hosseini A. Distribution of the mutated delta 32 allele of CCR5 co-receptor gene in Iranian population. Med J Islam Repub Iran 2014; 28: 140.
[PMID: 25694998]
[28]
Khorramdelazad H, Hakimizadeh E, Hassanshahi G, Rezayati M, Sendi H, Arababadi MK. CCR5 Δ 32 mutation is not prevalent in Iranians with chronic HBV infection. J Med Virol 2013; 85(6): 964-8.
[http://dx.doi.org/10.1002/jmv.23510] [PMID: 23588722]
[29]
Heydarifard Z, Tabarraei A, Moradi A. Polymorphisms in CCR5Δ32 and risk of HIV-1 infection in the southeast of caspian sea, Iran. Dis Markers 2017; 2017(1): 1-5.
[http://dx.doi.org/10.1155/2017/4190107] [PMID: 29209099]